Nanalysis
Financials
Estimates*
| CAD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 8.4m | 8.4m | 7.9m | 16.0m | 24.8m | 28.5m | 42.0m |
| % growth | - | - | (6 %) | 104 % | 55 % | 15 % | 48 % |
| EBITDA | <1m | 2.4m | (1.4m) | 2.0m | (4.8m) | (6.4m) | <1m |
| % EBITDA margin | 8 % | 29 % | (18 %) | 12 % | (20 %) | (22 %) | 1 % |
| Profit | <1m | (1.7m) | (3.7m) | (1.8m) | (9.9m) | (16.8m) | - |
| % profit margin | 1 % | (20 %) | (47 %) | (11 %) | (40 %) | (59 %) | - |
| EV / revenue | - | - | 4.0x | 6.9x | 2.8x | 1.3x | 1.2x |
| EV / EBITDA | - | - | -22.3x | 56.9x | -14.2x | -6.0x | 123.0x |
| R&D budget | - | - | <1m | <1m | 1.5m | <1m | - |
| R&D % of revenue | - | - | 6 % | 4 % | 6 % | 2 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | CAD1.6m | Early VC | |
| N/A | $1.0m | Early VC | |
| N/A | CAD750k | Series A | |
| N/A | N/A | IPO | |
| N/A | $100k | Convertible | |
| N/A | $2.7m | Grant | |
| N/A | N/A | Post IPO Equity | |
| N/A | CAD11.0m | Post IPO Equity | |
* | N/A | $12.3m | Secondary |
* | N/A | $2.9m | Private Placement VC |
* | CAD5.0m | Support Program | |
* | N/A | $3.5m | Post IPO Equity |
* | N/A | $5.0m | Post IPO Equity |
* | $1.5m | Grant | |
| Total Funding | CAD18.4m | ||
Related Content
Recent News about Nanalysis
EditNanalysis Scientific Corporation is a publicly traded company specializing in the development and manufacturing of compact Magnetic Resonance Imaging (MRI) and Nuclear Magnetic Resonance (NMR) spectroscopy products. Operating in the global scientific instrumentation market, Nanalysis serves a diverse range of clients including academic institutions, pharmaceutical companies, and industrial laboratories. The company's core product line includes benchtop NMR spectrometers, high field NMR consoles, and MRI consoles, which are known for their ease of use, low maintenance, and affordability. Nanalysis generates revenue through the sale of these instruments, as well as through software packages and service contracts. Their business model focuses on providing high-resolution, portable solutions that save time and space for their clients, making advanced magnetic resonance technology accessible to smaller labs and institutions. The company is listed on the TSXV under the ticker NSCI, FRA under 1N1, and USA OTC under NSCIF.
Keywords: benchtop NMR, MRI consoles, spectroscopy, academic labs, pharmaceutical, industrial labs, high resolution, portable, low maintenance, affordable.